INBS
Intelligent Bio Solutions Inc. NASDAQ Listed Dec 23, 2020$1.72
+2.99%
vs $1.67
Mkt Cap $5.7M
52w Low $1.52
0.9% of range
52w High $24.90
50d MA $2.12
200d MA $3.97
P/E (TTM)
—
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.1x
ROE
-99.1%
P/FCF
-0.1x
RSI (14)
10.60
ATR (14)
$0.14
Beta
4.59
50d MA
$2.12
200d MA
$3.97
Avg Volume
228.8K
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
142 West 57th Street · New York City, NY 10019 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | TNS | -1.58 | -0.90 | +43.0% | 2.67 | +0.9% | -0.7% | -5.3% | -0.4% | -5.6% | -4.2% | — |
| May 12, 2026 | TNS | 1.40 | -1.80 | -228.6% | 3.18 | +10.1% | +25.5% | +3.0% | -2.4% | -9.0% | -9.9% | — |
| Feb 12, 2026 | TNS | 0.40 | -2.82 | -805.0% | 4.90 | -2.0% | +2.4% | -4.2% | +0.4% | -1.4% | -4.2% | — |
| Nov 13, 2025 | TNS | -1.50 | -3.50 | -133.3% | 7.17 | -1.0% | +0.4% | -3.9% | -0.3% | -0.7% | -6.3% | — |
| Nov 12, 2025 | AMC | -1.50 | -3.50 | -133.3% | 7.93 | -2.1% | -9.6% | +0.4% | -3.9% | -0.3% | -0.7% | — |
| Aug 15, 2025 | TNS | -1.20 | -3.60 | -200.0% | 14.70 | +0.0% | +2.0% | -2.7% | -2.1% | +2.8% | +0.7% | — |
| May 14, 2025 | TNS | -2.80 | -4.40 | -57.1% | 12.85 | -5.1% | -3.5% | -1.6% | +1.2% | +3.6% | -2.0% | — |
| May 13, 2025 | AMC | -2.80 | -0.44 | +84.3% | 13.60 | +0.0% | -5.1% | -3.9% | -1.6% | +1.6% | +3.2% | — |
| Feb 14, 2025 | TNS | -3.20 | -5.00 | -56.2% | 25.50 | +3.5% | -2.7% | +6.5% | -20.5% | +5.2% | +0.9% | — |
| Feb 13, 2025 | AMC | -3.20 | -0.50 | +84.4% | 23.70 | +1.7% | +7.6% | -2.7% | +6.5% | -20.5% | +5.2% | — |
| Nov 13, 2024 | TNS | -0.53 | -0.70 | -32.1% | 17.00 | -1.8% | -10.6% | -2.6% | -4.7% | -2.1% | +1.4% | — |
| Nov 7, 2024 | AMC | -0.53 | -0.70 | -32.1% | 17.20 | +5.8% | -5.2% | +12.9% | +5.4% | -12.4% | -10.6% | — |
| Sep 19, 2024 | TNS | -0.51 | -1.34 | -162.7% | 18.00 | +1.7% | +4.4% | -8.5% | +2.9% | +7.9% | -3.1% | — |
| May 9, 2024 | TNS | -0.87 | -1.43 | -64.4% | 24.70 | +3.2% | -5.3% | +3.0% | -0.8% | -2.1% | +1.7% | — |
| May 8, 2024 | AMC | -0.87 | -1.43 | -64.4% | 25.00 | -1.6% | -1.2% | -5.3% | +3.0% | -0.8% | -2.1% | — |
| Feb 9, 2024 | TNS | -32.40 | -20.70 | +36.1% | 67.70 | -25.7% | -11.4% | -9.8% | -5.4% | -4.9% | -9.2% | — |
| Nov 23, 2023 | TNS | -7.68 | -12.48 | -62.5% | — | — | — | — | — | — | — | — |
| Nov 8, 2023 | AMC | -7.68 | -12.48 | -62.5% | 27.30 | +60.4% | +92.3% | +32.0% | -9.5% | +6.2% | +2.6% | — |
| Aug 24, 2023 | AMC | -1.99 | -2.29 | -15.1% | 219.70 | -0.5% | -0.5% | +2.2% | +7.5% | -9.0% | -3.3% | — |
| May 11, 2023 | AMC | -2.07 | -24.37 | -1077.3% | 354.10 | +1.7% | -5.4% | +6.4% | -4.0% | -3.5% | +7.5% | — |
No analyst ratings available.
No insider trades available.
8-K · 8.01
!! High
Intelligent Bio Solutions Inc. -- 8-K 8.01: Material Event / Announcement
Sep 11
8-K · 8.01
!! High
Intelligent Bio Solutions Inc. -- 8-K 8.01: Material Event / Announcement
Sep 9
8-K · 3.02
!! High
Intelligent Bio Solutions Inc. -- 8-K 3.02: Unregistered Securities Offering
Sep 2
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 1
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 28
8-K · 2.02
!! High
Intelligent Bio Solutions Inc. -- 8-K 2.02: Earnings Results
Aug 19
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 11
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 5
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 3
8-K · 8.01
!! High
Intelligent Bio Solutions Inc. -- 8-K 8.01: Material Event / Announcement
Aug 3
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 23
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 21
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 16
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Intelligent Bio Solutions received market clearance for its Intelligent Fingerprinting Drug Screening System to detect codeine, expanding its diagnostic capabilities and potential revenue opportunities.
Jun 2
8-K · 2.02
!! High
Intelligent Bio Solutions Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 8.01
!! High
Intelligent Bio Solutions Inc. -- 8-K 8.01: Material Event / Announcement
Intelligent Bio Solutions (INBS) increased outstanding shares through warrant exercises and an at-the-market offering agreement with Ladenburg Thalmann, diluting existing shareholders.
Apr 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Harry Simeonidis received 21,350 performance-vesting shares, creating potential dilution while tying executive compensation to future performance metrics, which could incentivize value creation but increases shareholder dilution risk.
Mar 23
8-K · 7.01
! Medium
Intelligent Bio Solutions Inc. -- 8-K 7.01: Regulation FD Disclosure
Intelligent Bio Solutions disclosed material information via press release but provided no specific operational or financial details in this 8-K filing.
Feb 25
8-K
Intelligent Bio Solutions Inc. -- 8-K Filing
Intelligent Bio Solutions reported Q2 2026 financial results and provided a business update, though specific revenue or profitability metrics were not disclosed in this announcement.
Feb 12
8-K
Intelligent Bio Solutions Inc. -- 8-K Filing
Intelligent Bio Solutions (INBS) reports strong preliminary revenue growth across all product categories for Q2 and H1 2026, signaling positive momentum in its non-invasive testing solutions business.
Feb 5
Institutional (13F) — Top 3
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.p. | 37,956 | $127K | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 5,810 | $13K | — | Jun 2026 |
| 3 | Ubs Group Ag | 372 | $1K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 7,359 | $33K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 1,769 | $5K | May 2026 |
| 3 | Fidelity Total Market Index Fund | 409 | $1K | May 2026 |
| 4 | Blackstone Alternative Multi-Strategy Fund | -30 | $-69 | Jun 2026 |
Valuation
Market Cap
$5.7M
Enterprise Value
-$139K
P/E (TTM)
—
Forward P/E
0.49x
PEG Ratio
0.01x
P/B
0.32x
P/S
0.22x
P/FCF
-0.09x
EV/EBITDA
—
Shares Out
527K
Financials (TTM)
Revenue
$4.2M
Net Income
-$12.4M
EBITDA
-$11.5M
Free Cash Flow
-$9.9M
Op Cash Flow
-$9.7M
EPS Basic
$-20.00
EPS Diluted
$-9.46
EPS Forward
$3.50
Gross Margin
27.7%
Op Margin
-305.0%
Net Margin
-294.9%
Balance Sheet
Total Assets
$8.2M
Total Liab.
$5.4M
Total Equity
$2.8M
Cash
$1.0M
LT Debt
$0
Book Value/Sh
$5.34
Debt/Equity
0.09x
Current Ratio
0.77
Quick Ratio
0.65
Returns & Growth
ROE
-99.1%
ROA
-62.3%
ROIC
-334.7%
Rev Growth YoY
-1.9%
EPS Growth YoY
+68.7%
Price Returns
2W
-15.2%
1M
-31.3%
3M
-25.1%
6M
-46.5%
12M
-83.9%
Technicals
52W High
$24.90
52W Low
$1.52
50d MA
$2.12
200d MA
$3.97
RSI (14)
10.60
ATR (14)
$0.14
Beta
4.59
Avg Volume
229K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 3:28pm
· Source: financialmodelingprep.com